Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus.

Shintaro NakamuraYasutaka MiyachiAkihito ShinjoHisashi YokomizoMasatomo TakahashiKohta NakataniYoshihiro IzumiHiroko OtsukaNaoichi SatoRyuichi SakamotoTakashi MiyazawaTakeshi BambaYoshihiro Ogawa

Published in: Journal of cachexia, sarcopenia and muscle (2023)

This study highlights the potential role of the AICARP/AMPK pathway in oxidative rather than glycolytic skeletal muscles during SGLT2 inhibition, providing novel insights into the mechanism by which SGLT2 inhibitors improve endurance capacity in patients with type 2 diabetes.

Keyphrases

skeletal muscle
high intensity
resistance training
protein kinase
nuclear factor
immune response